Pharma POOL Dr. Peter KRUSE Tom MARTIN Dr. Brett E. SKOLNICK Novo Nordisk Expands Clinical Development Staff in U.S. BioPharmaceuticals Division, Promotes IT Staff Member Novo Nordisk has announced the appoint ment of Brett E. Skolnick, Ph.D., as director of clinical research, and Peter Kruse, M.D., Ph.D., as associate medical director in its U.S. BioPharmaceuticals business unit. Novo Nordisk’s U.S. headquarters are in Princeton, N.J., and its global base is in Denmark. In their new positions, Dr. Skolnick and Dr. Kruse will be responsible for establishing new clinical research involving new indica tions for the company’s biopharmaceutical product NovoSeven Coagulation Factor VIIa (recombinant). Dr. Skolnick is a neuroscientist with an 18 year academic career on faculty at the Univer sity of Pennsylvania where he retains a title of adjunct associate professor. While there, he initiated and directed the acute stroke clinical trials unit as well as established and directed the Stereotactic Neurosurgical Program. He joins Novo Nordisk following a threeyear tenure with Quintiles Inc., a multinational contract research organization. While with the company, he served as executive director for CVA, a neurologyfocused division, and later as executive director of Drug and Device Development Solutions, a Quintiles consult ing group working with most of the major pharmaceutical companies. Dr. Skolnick received his doctorate and master’s degrees in human psychophysiology from Washington University in St. Louis and his bachelor’s degree in psychology from the University of Maryland in College Park. He did a twoyear postdoctoral fellowship at the University of Pennsylvania before joining the clinical faculty. Dr. Kruse joined Novo Nordisk’s interna tional marketing team in 2000. He served as international medical advisor, supporting the scientific knowledge of the NovoSeven project on preclinical and clinical protocols, as well as strategic needs in international marketing. Before joining the company, Dr. Kruse served as a physician in the Danish Navy. Dr. Kruse trained in general surgery at University Hospitals of Copenhagen with a special focus on gastrointestinal surgery. Dr. Kruse has 12 years of clinical experi ence. He received his medical and doctorate degrees from the University of Copenhagen, Denmark. In other company news, Novo Nordisk has promoted Tom Martin to director of informa tion technology in the U.S. Mr. Martin served as IT project manager before his promotion. In his new position, Mr. Martin is charged with developing the compa ny’s U.S. IT strategy and leading his depart ment’s implementation of the plan. Additionally, he will serve as the North American representative of Novo Nordisk’s global IT board, which oversees the multina tional company’s worldwide information tech nology initiatives. A 10year Novo Nordisk veteran, Mr. Mar tin has been responsible for designing and implementing a computing infrastructure and environment for the company’s U.S. clinical trials program. Mr. Martin received a bachelor’s degree in mathematics from Rutgers University and is certified in macroscope development method ology. Maurice A. RENSHAW Marc E. ROBINSON President of Pfizer’s Consumer Healthcare Division to Retire Maurice A. Renshaw, VP of Pfizer, execu tive VP of the Pfizer Consumer Group, and president of the Pfizer Consumer Healthcare Division, has announced his intention to retire early in 2003. Pfizer, New York, discovers, develops, manufactures, and markets lead ing prescription medicines for humans and animals and many of the world’s best known overthecounter brands. Mr. Renshaw rapidly advanced through a series of marketing and gen eral management positions in several countries with responsibility for consumer products and prescription pharmaceuticals in Asia, Europe, and the Americas. As president of Warner Lambert Japan, Mr. Renshaw led a threefold growth in the size of the business in the early 1990s with the development and execution of key strategic initiatives in pharmaceuticals and particularly in Adams and Schick con sumer products. From 1996 to June 2000, Mr. Renshaw served as president of ParkeDavis USA; in 1998, WarnerLambert appointed him a cor porate VP. During this fouryear period, he led the WarnerLambert pharmaceutical business to unprecedented growth of more than 500% to $6 billion and was responsible for the suc cessful launch of Lipitor. A native of Australia, Mr. Renshaw received a bachelor of pharmacy degree from Sydney University. Marc E. Robinson, currently president of Pfizer Consumer Healthcare’s North America region, has been named the new president of the Consumer Healthcare Division. Mr. Robinson will serve as a member of the Pfizer Management Council. A graduate of the University of Michigan with a B.A. in economics and a MBA in mar keting, Mr. Robinson joined WarnerLambert in 1986. He served in a variety of consumer healthcare and confectionary marketing posi tions, both domestic and international, of increasing responsibility. In 1996, Mr. Robinson was appointed gen eral manager, European Business Process Improvement, responsible for the successful implementation of major information tech nology advances. In 1999, he became regional president of WarnerLambert in Australia and New Zealand, managing all aspects of the pharma ceutical, consumer healthcare, and shaving products businesses as well as manufacturing. Mr. Robinson became president of Pfizer Con sumer Healthcare’s North America region in 2000. 88 F e b ru a r y 20 03 PharmaVOICE TALENT POOL EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY Dr.Tushar P. SHAH Altana Pharma U.S. Appoints Senior VP, Scientific and Clinical Affairs Tushar P. Shah, M.D., has joined Altana Pharma U.S., the pharmaceutical division of Germany based Altana AG, as senior VP of scientific and clinical affairs. Dr. Shah will be responsible for all clinical and regulatory functions on behalf of Altana Pharma U.S., which is based in Florham Park, N.J. This role includes overseeing regulatory submissions and interactions with FDA repre sentatives and clinical research activities. Dr. Shah comes to Altana Pharma U.S. after a nineyear career at GlaxoSmithKline where he worked primarily in respiratory and inflammation clinical research and develop ment. While at GlaxoSmithKline, he was responsible for clinical development plans for new drugs for chronic obstructive pulmonary disease, asthma, and rhinitis. Dr. Shah holds a medical degree from the Hershey Medical College at the Pennsylvania State University. He com pleted his residency in internal medicine at the University of North Carolina and fellowship in allergy and clinical immunology at Johns Hopkins Univer sity. Dr. Nancy L. SNYDERMAN Johnson & Johnson Appoints VP, Medical Affairs Nancy L. Sny derman, M.D., has joined Johnson & Johnson, New Brunswick, N.J., in the newly created position of VP of medical affairs, cor porate staff, for the healthcare corporation. Dr. Snyderman will advise the corpo ration and its affiliated companies on the introduction of new technologies across Johnson & Johnson’s lines of consumer, pharmaceutical, medical device, and diagnostics businesses. Previously Dr. Snyderman had worked at ABC News as a medical cor respondent, and had an active practice of head and neck surgery. Dr. Snyderman attended medical school at the Universi ty of Nebraska and followed up with residen cies in pediatrics and ear, nose, and throat surgery at the University of Pittsburgh. Biotech POOL Dr. Debby Jo BLANK Genencor’s Chief Business Officer, Healthcare Resigns Debby Jo Blank, M.D., has resigned as Genencor International Inc.’s chief business offi cer for healthcare to pursue other opportunities. Genencor International, Palo Alto, Calif., is a diversified biotechnology company that develops and delivers innovative products and services into the healthcare, agriprocessing, industrial, and consumer markets. The compa ny remains committed to its strategy of build ing a presence in drug discovery and develop ment and will conduct a search for a successor. “Debby Jo Blank has provided excellent leadership in the development of our health care strategy and business development team,” says Jean Jacques Bienaime, CEO and presi dent of Genencor. “We wish her the best of luck in the future.” Daniel GREENLEAF Nabi Biopharmaceuticals Names Senior VP, Operations Nabi Biopharmaceuti cals has appointed Daniel Greenleaf to the newly created position of senior VP of operations. Nabi Biopharmaceuticals, Boca Raton, Fla., discovers, develops, manufactures, and markets products that power the immune system to help people with serious, unmet medical needs. Mr. Greenleaf joins Nabi Biopharmaceuti cals from ScheringPlough Corp. where he has held a number of senior level positions, most recently as VP of marketing and sales. 89 PharmaVOICE F e b ru a r y 2 00 3 TALENT pool Ken COPELAND Ken Copeland, senior director for IMS Statisti cal Services, has received one of two inaugural Dis sertation Fellowships from the U.S. Bureau of Labor Statistics (BLS). The BLS is the federal gov ernment’s principal factfinding agency for labor economics and statistics. The fellowships were developed to advance research in the field of survey design and analysis. Mr. Copeland’s work will focus on investigating new statistical approaches called nonresponse adjustment statistics to improve the accuracy and stability of incomplete data received over time. A peer review board representing the BLS and academia evaluated and selected Mr. Copeland for this fellowship based on the value and scientific merit of the proposed research, project feasibility, and the candidate’s academic performance. This research was motivated by Mr. Copeland’s ongoing work at IMS to ensure that clients consis tently receive the most accurate information possi ble, despite occasional gaps in information received from individual data suppliers. “We are honored to have Ken’s work recognized with such a prestigious award,” says Paul Wilson, IMS VP of statistical services. “He continues to make invaluable contributions in his field and to IMS, and we are privileged to support and benefit from his outstanding work.” In addition to his ongoing work at IMS, Fair f i e l d , C o nn . , M r . Copeland is pursuing a P h . D . i n s u r v e y methodology at the University of Maryland. He is the first doctoral candidate accepted into the Joint Program in Survey Methodology, a graduate degree pro g r am empha s i z i ng stateoftheart princi ples and practices in the design, analysis, and evaluation of sample surveys. Mr. Copeland joined IMS in 1990 and has developed and implemented survey method ologies for the physician, hospital, pharmacy, and clinic segments of IMS’s business. He has more than 25 years experience in largescale household, establishment, and healthcare sur veys and has published articles in Scrip maga zine, The Journal of Pharmaceutical Marketing, and Management and Drug Benefit Trends, as well as other leading industry publications. Mr. Copeland received his M.S. in statistics from the University of Kentucky and his B.S. in mathematics from the University of Day ton. IMS SENIOR DIRECTOR AWARDED FELLOWSHIP FROMU.S. BUREAU OF LABOR STATISTICS Ken Copeland is the first doctoral candidate to be accepted into the Joint Program in Survey Methodology, a graduate degree program emphasizing stateofthe art principles and practices of sample surveys. TALENT pool At ScheringPlough, Mr. Greenleaf held a number of increasingly responsible sales, mar keting, and strategic venture positions, including the creation of a wholly owned, global subsidiary. Before joining Schering Plough, Mr. Greenleaf spent six years in the U.S. Air Force, where he was a captain and navigator and coordinated missions for world wide tactical airlift operations, including Operation Desert Storm. Mr. Greenleaf received a B.A. in economics from Denison University, and a MBA from the University of Miami. Bob HAMM Dr.Whaijen SOO Biogen Names Senior VP, Medical Research,and Senior VP,North American Commercial Operations Biogen Inc. has appointed Whaijen Soo, M.D., Ph.D., senior VP of medical research. Dr. Soo will oversee all medical research activ ities and will serve as a member of the research and development management team. Biogen, Cambridge, Mass., is a biotechnology compa ny principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Dr. Soo joins Biogen following a distin guished 17year career with Roche Global Development, where he most recently served as VP of clinical sciences and was responsible for global strategic planning. During his tenure with Roche, Dr. Soo headed the oncol ogy, virology, and transplant areas and built Roche’s genomics and bioinformatics capabil ities. In addition, Dr. Soo was responsible for the integration of diagnostics with pharma ceutical business strategy. Dr. Soo earned a B.S. in chemistry from the National Taiwan University and graduated with a Ph.D. in biochemistry from the Uni versity of California at Berkeley. He attended the University of California at San Francisco Medical School and performed his residency in internal medicine at Brigham and Women’s Hospital, Harvard Medical School. In addition, Biogen has appointed Bob Hamm senior VP of North American com mercial operations. In this newly created posi tion, Mr. Hamm will oversee Biogen’s U.S. neurology business unit, U.S. dermatology business unit, U.S. com mercial services, and Canadian operations. Mr. Hamm joined Biogen in 1994 as associ ate director of logistics. In that position, he estab lished Biogen’s supply chain and played a major role in the company’s transformation from a research organization to an operating company in 1996. Following an assignment in Europe from 1996 to 1999, Mr. Hamm was named VP of manufacturing and engineering for Bio gen. In 2001, he was appointed head of sales and marketing of North America. In 2002, Mr. Hamm was appointed senior VP or Europe, Canada, and the Middle East. Dr. Sebastian KOSSEK Robert MENZI Dr. Mohan NATESAN Raj PRABHAKAR Tim SEELEY Dr. Shanxiang SHEN Protiveris Appoints New ManagementTeam Responsible for Corporate Development and Product Commercialization Protiveris Inc., a bionanotechnology com pany commercializing proprietary bioMEMs technologies to facilitate protein research and the discovery of new pharmaceuticals, has appointed its executive management team. This team is charged with strategic corporate development and the commercialization of Protiveris proprietary microcantilever tech nology. The Protiveris executive management team includes: Robert Menzi, chief operating officer; Sebastian Kossek, Ph.D., chief scientif ic officer; Tim Seeley, VP of engineering; Raj Prabhakar, director of strategic planning and business development; Mohan Natesan, Ph.D., director of surface chemistry; and Shanxiang Shen, M.D., Ph.D., director of pro teomics and biochemistry. Before joining Protiveris, Rockville, Md., Mr. Menzi was part of the corporate develop ment staff at Raytheon Co., where he oversaw the valuation process for potential acquisi tions, joint ventures, and divestitures and suc cessfully led the business case development of a major TransAtlantic joint venture. Mr. Menzi is responsible for leading Protiveris through all phases of commercial development and business execution, and preparing the company for followon rounds of financing. Dr. Kossek’s professional experience includes biosensor research at the Laboratory for micro and nanostructures at the Paul Scherrer Institut, and management positions at Molecular Imaging, a leading scanning probe instrumentation manufacturer. Dr. Kossek is directing Protiveris’ R&D efforts and is responsible for all scientific and techni cal aspects of product development. Mr. Seeley joined Protiveris in 2000 as a principal development engineer and is respon sible for overseeing the overall design and implementation of the biosensor reader sys tems. Mr. Seeley’s prior experience includes 17 years at the Naval Research Laboratory, where he developed space flight instrumentation and ground support equipment, and the Naval Center For Space Technology. Mr. Prabhakar’s professional experience includes technology and biotechnology ven ture capital, private equity, finance, and growth startups in both the U.S. and Asia. Before joining Protiveris, Mr. Prabhakar was responsible for corporate development and strategic planning at Osiris Therapeutics, a stemcell therapeutics company. Mr. Prab hakar is responsible for overall corporate and business development efforts targeting the protein biochip market. As director of surface chemistry, Dr. Nate san is responsible for the development and evaluation of suitable surface chemistries for cantilever immobilization of proteins. Before joining Protiveris, Dr. Natesan acquired rele vant skills in biosensor development at the Naval Research Laboratory in Washington D.C., where he designed and developed mag netic force microscopybased biosensors for the detection of biowarfare agents. Before joining Protiveris, Dr. Shen was a staff fellow at the Oral Infection and Immunity branch of the National Institutes of Health, and a staff fellow at the Laboratory of Biochemistry and Metabolism at the National Institute of Diabetes, Digestive, and Kidney Diseases at NIH. Dr. Shen is responsible for assay develop ment and optical reader validation. Thomas P. MATHERS President and CEO Named at Cell Based Delivery Cell Based Delivery Inc. has named Thomas P. Mathers, president and CEO. Mr. Mathers, 36, also has been elected to the company’s board of direc tors, bringing the total board membership to seven. Cell Based Delivery, Providence, R.I., is a privately held biotechnol ogy company developing implantable protein delivery systems to treat chronic and life threatening disease. Mr. Mathers has more than 11 years of exec utive management, sales, and marketing expe rience in the lifesciences and medicaldevice industry. He served most recently as VP and general manager of Cardion Pharmaceuticals Inc. Mr. Mathers also served as a management 90 F e b ru a r y 20 03 PharmaVOICE TALENT pool board member for its parent company, Cardion AG in Dusseldorf, Germany. Before Cardion, he was with Genzyme Corp. for seven years, as VP of strategic development. In this capacity, he was responsible for Genzyme’s cardiovascular therapeutics development, business develop ment, and marketing activities. He earned his bachelor of science degree in engineering from the U.S. Military Academy at West Point. David P. WRIGHT GenVec Appoints President and Chief Operating Officer GenVec Inc., a biopharmaceutical company developing genebased medicines, has appoint ed David P. Wright as president and chief oper ating officer. GenVec, Gaithersburg, Md., is a publicly held biotechnology company focused on the development and commercialization of novel genebased therapies that produce medi cally beneficial proteins at the site of disease. Mr. Wright joins GenVec after serving as president and chief business officer, and previ ously executive VP of commercial operations, for Guilford Pharmaceuticals. Before Guil ford, Mr. Wright served as executive VP for MedImmune Inc. DrugDelivery POOL Dr. Gordon BRANDT Nastech Appointment Further Strengthens Executive Management Team Nastech Pharmaceutical Co., Bothell, Wash., has appointed Gordon Brandt, M.D., as executive VP of science and clinical devel opment. Dr. Brandt brings more than 20 years of experience in the medical field to Nastech, which specializes in nasal drugdelivery tech nology. Before joining Nastech, Dr. Brandt held senior positions at Sonus Pharmaceuticals Inc. and was most recently VP of clinical and regu latory affairs, where he was involved in manag ing all aspects of design and implementation of early and latestage clinicaltrial programs and submissions to regulatory authorities. Dr. Brandt graduated from Yale Universi ty, received a medical degree from the Univer sity of California, San Francisco, and complet ed a residency in internal medicine at Kaiser Hospital, San Francisco. Dr. Brandt is an author on numerous scientific papers and abstracts and holds one U.S. patent. Genomic POOL Dr. John MARAGANORE Alnylam Pharmaceuticals Appoints President and CEO Alnylam Pharmaceu ticals Inc., a therapeutic RNA interference compa ny based in Cambridge, Mass., has appointed John M. Maraganore, Ph.D., as president and CEO. Dr. Maraganore is the former senior VP of strategic product development at Millennium Pharma ceuticals. RNAi is a naturally occurring cellu lar process being adapted for therapeutic application because of its ability to specifically inactivate pathological genes. RNAi repre sents a new approach to therapy that may treat a diverse range of human diseases, including cancer, infectious disease, autoimmune dis ease, and metabolic disorders. During his sixyear tenure at Millennium Pharmaceuticals, Dr. Maraganore played a number of key roles, including building and leading Millennium’s global therapeutic area franchise businesses. He previously was respon sible for merger and acquisition, strategic plan ning, and inlicensing activities, and was gener al manager and founder of Millennium BioTherapeutics. Dr. Maraganore received his masters and Ph.D. degrees from the University of Chicago’s Department of Biochemistry and Molecular Biology. Specialty POOL Dr. Ian CRITCHLEY Dr. Garry DALLMANN Dr. Burton GOODMAN Donald MORRISSEY Replidyne Appoints VP, Corporate Development,and Scientific Directors Replidyne, a drugdiscovery company, has appointed a VP of corporate development and three scientific directors to its management team. Donald Morrissey recently joined Repli dyne, Louisville, Colo., as VP of corporate development. Before that he was VP of legal affairs and business development for Caliper Technologies. Before that, Mr. Morrissey was a business attorney with Cooley Godward, a Sili con Valley law firm. Mr. Morrissey received a law degree from the University of Southern California Law School and a bachelor’s degree from the University of Colorado. Burton Goodman, Ph.D., has joined the company as director of informatics and automa tion. Dr. Goodman has 15 years of medicinal chemistry, combinatorial chemistry, automa tion, and IT experience in the pharmaceutical industry. His most recent positions included senior director of highthroughput production at SomaLogic and director of chemistry and automation at Molecumetics. Dr. Goodman holds a Ph.D. in synthetic organic chemistry from Columbia University. Garry Dallmann, Ph.D., has been appoint ed director of lead discovery. Dr. Dallmann spent three years as a scientist in the antimi crobial and lead discovery departments at Tularik and three years as a senior scientist in the antifungal group at RiboGene Inc. (now Questcor Inc.). He received his Ph.D. in bio chemistry at the University of Western Ontario in London. His postdoctoral work was done at the University of Colorado Health Sci ences Center in Denver in the laboratory of Dr. Charles McHenry, a founder of Replidyne. In addition, Ian Critchley, Ph.D., has joined Replidyne as director of microbiology. Dr. Critchley brings more than 15 years of experi ence in antibacterial drug discovery and develop ment. Before joining Replidyne, Dr. Critchley was director of laboratory services at Focus Tech nologies. He obtained his Ph.D. in microbiology from the University of Glasgow in Scotland. Dr. Sydney GILMAN James B. SLOAN Jr. aaiPharma Names Two New Executives aaiPharma, Wilmington, N.C., has announced the addition of two new executives. James B. Sloan Jr., joins the company as senior VP of corporate finance, and Sydney Gilman, Ph.D., joins aaiPharma as VP of regulatory affairs and quality assurance. Mr. Sloan joins aaiPharma from PPD Inc. where he managed the investor relations pro gram, corporate banking relationships, and the global risk management program. With more than 15 years of finance experience, Mr. Sloan directs aaiPharma’s investor relations activities. Mr. Sloan earned a masters in international business studies from the University of South 92 F e b ru a r y 20 03 PharmaVOICE TALENT pool Carolina, and a bachelor of arts in economics from Washington and Lee University. Dr. Gilman joins aaiPharma from Elan Phar maceuticals where he directed the U.S. regulato ry affairs activities for its painmanagement products. With more than 20 years of research, regulatory affairs, and quality assurance experi ence in the pharmaceutical industry, Dr. Gilman leads aaiPharma’s regulatory affairs and corpo rate quality assurance efforts. Dr. Gilman also served as a reviewer within CDER at the U.S. Food and Drug Administration for several years. Dr. Gilman earned a Ph.D. in organic chemistry from the University of Pittsburgh. Emerging POOL Dr. Alison PILGRIM Avera Pharmaceuticals Names Chief Medical Officer Avera Pharmaceuticals Inc., a private, developmentstage pharmaceutical company, has named Alison Pilgrim, B.M. B.Ch., D.Phil., to the newly created position of chief medical officer. Dr. Pilgrim brings to Avera, San Diego, more than 17 years experience in clinical drug development within the pharma ceutical industry, having served most recently as senior VP of global clinical development at Elan. As chief medical officer, Dr. Pilgrim is charged with leading the clinical development of Avera’s portfolio of neuroscience compounds. She has extensive international experience in the clinical development of neurology, metabol ic, antiinflammatory, cardiovascular, and HIV compounds. In addition to serving as senior VP of clinical development of biopharmaceuticals for Elan Corp., Dr. Pilgrim has held senior clin ical positions at Glaxo, Sanofi, and DuPont Pharmaceuticals. Dr. Pilgrim was awarded her medical degree and doctorate of philosophy by Oxford University. Service POOL Richard C. BLEIL New President and COO for iPhysicianNet iPhysicianNet has appointed Richard C. Bleil as president and chief operating. iPhysi cianNet, Scottsdale, Ariz., created the e detailing space, and provides live, facetoface, interactive video detailing. Mr. Bleil has extensive experience in the healthcare industry, and most recently held executive positions at WebMD and Medical Manager. Before these roles, Mr. Bleil headed WellPoint Pharmacy Management, a division of WellPoint Health Networks. Mr. Bleil is responsible for the daytoday management of the business of the company. Ronald E. BRANDT Ricerca Biosciences Creates Executive VP of Marketing and Sales Position Ricerca Biosciences, a worldwide drug develop ment partner to biotech nology and pharmaceuti cal companies and a provider of contract ser vices, has appointed Ronald E. Brandt to the newly created position of executive VP of marketing and sales. Mr. Brandt brings to Concord, Ohiobased Ricer ca more than 20 years of extensive experience in business development and sales in the phar maceutical industry. Most recently, Mr. Brandt held senior level positions at International Specialty Products, including executive of sales and business development, and senior VP of sales for the Americas. Mr. Brandt received a MBA from Rutgers University and a B.E. in chemical engineering from The Cooper Union. Dr. Jeffrey O.BRUBAKER Jennifer DAVENPORT Tom DRAKE Laurie ERMENTROUT Linda HENSON Wendy HENSON Julie HOLCOMBE Stacy O’DONNELL Elaine RUDELL Paul SUAREZ OCC Announces Staff Promotions and Additions OCC North America Inc., a healthcare communications compa ny with offices in New town, Pa., has promoted Jennifer Davenport to VP and account supervisor, from account director. The company also has promoted Laurie Ermen trout to VP and account supervisor from account director. In addition, OCC has announced new hires. Jef frey O. Brubaker, Ph.D., has joined OCC as senior scientific writer. Dr. Brubaker joins the com pany from Adis Interna tional where he was a medical writer. Tom Drake has been hired as VP and account director. Mr. Drake joins OCC from Interlink Healthcare Communica tions where he was VP and account supervisor for global and domestic accounts. Linda Henson has joined OCC as senior medical writer. Ms. Henson previously was a director of medical writing at Toltzis Commu nications/Medical Education Group. Wendy Henson has joined OCC as CME coordinator. Ms. Henson joins from Medical Education Group, where she was manager and accreditation services/continuing education coordinator. Julie Holcombe has joined the company as VP and director of The Oxford Institute. Ms. Holcombe previously was director of ebusiness at SimStar Internet Solu tions. Stacy O’Donnell has joined the company as account director. Ms. O’Donnell joins the com pany from Interlink Healthcare Communica tions where she was account manager. Elaine Rudell has joined the company as VP of professional relations. Ms. Rudell joins OCC from Health Learning Systems, where she was VP of professional rela tions. Paul Suarez has been added to the company as IT director. Mr. Suarez joins the company from Quadratix Corp. 93 PharmaVOICE F e b ru a r y 2 00 3 TALENT pool Jeff BURNETT FleishmanHillard Chicago Appoints Senior VP for Healthcare Practice FleishmanHillard Chicago has appointed Jeff Burnett as a senior VP in the office’s health care practice. Mr. Burnett brings to Fleishman Hillard more than 14 years of communications and marketing experience in prescription, over thecounter, and nutrition products for corpo rate and professional organizations. FleishmanHillard Chicago, a unit of FleishmanHillard Inc., St. Louis, offers Mid westbased companies counsel and expertise in the corporate, consumer marketing, investor relations, healthcare, crisis communications, and public affairs fields. Mr. Burnett joins FleishmanHillard from Manning, Selvage & Lee, where he was a deputy managing director and director of its Chicago healthcare practice. Before joining Manning, Selvage & Lee, he was at Edelman Public Relations Worldwide where he worked on a variety of healthcare business. Suzanne CHARLESTON Christine SIMMON GPhA Adds Key Staffers as Newly Elected Congress Prepares to Address High Drug Costs The Generic Pharmaceutical Association (GPhA) has named Christine Simmon as VP of policy and public affairs, and Suzanne Charleston as director of government relations. GPhA, Washington, D.C., represents the man ufacturers and distributors of finished generic pharmaceuticals, manufacturers, and distribu tors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Ms. Simmon and Ms. Charleston will help the association as it pre pares to work with Congress and President Bush to answer America’s call for more timely access to affordable pharmaceuticals. Most recently, Ms. Simmon was a senior policy analyst at BlueCross BlueShield Associ ation. Ms. Simmon also chaired the Policy Committee for the Rx Health Value Coalition, a group of employers, insurers, labor unions, providers, and consumer organizations active on pharmaceutical issues. Ms. Simmon received her J.D. from Georgetown Universi ty Law Center and her B.A. from Georgetown University. She is a member of the Maryland State Bar Association. Before joining GPhA, Ms. Charleston was director of government affairs at the Pharma ceutical Care Management Association, where she represented pharmacy benefit managers before Congress, state legislatures, governors, insurance commissioners, and regulatory agencies. Ms. Charleston brings more than 15 years of association and legislative experience to GPhA that includes managing government affairs and political action committees, as well as nationwide grassroots and public affairs campaigns. Ms. Charleston received her B.A. from the University of Maryland. Lloyd FISHMAN Beth R. JACOBSON John MUSANTE PDI Announces Promotion and Addition of Members to the Executive Team PDI Inc., a commercial sales and market ing partner to the biopharmaceutical and medical devices and diagnostics industries, has announced several executive promotions and additions. Lloyd Fishman has been promoted to the position of executive VP and general manager, medical devices and diagnostics of the Upper Saddle River, N.J.based company. Mr. Fish man has been with PDI since January 2001, in the capacity of VP and general manager of the MD&D business. Before joining PDI, Mr. Fishman spent 25 years within the medical device industry with companies such as John son & Johnson, CR Bard, Becton Dickinson, and Ohmeda. Beth R. Jacobson has joined the company as executive VP and general counsel. Ms. Jacobson joins PDI after 15 years with Skadden, Arps, Slate, Meagher and Flom. She is a graduate of New York University School of Law. John Musante has joined the company as VP of corporate development. Mr. Musante’s primary responsibility is to identify and pur sue pharmaceutical products to be promoted by PDI’s Products Group. Before joining PDI, Mr. Musante founded AcSentient Inc., a spe cialty pharmaceutical company. Before AcSen tient, Mr. Musante was a senior VP and part ner at Rockett, Burkhead & Winslow. Rachel KESSLER Belsito & Company Hires VP, Director of Media Relations Belsito & Co. has appointed Rachel Kessler as VP and director of media relations. Ms. Kessler brings more than 12 years of experi ence in public relations and national print and broadcast journalism to the agency. Before joining Belsito, New York, Ms. Kessler was president of RKA Media Rela tions LLC, and previously was a media rela tions specialist in the healthcare practices at two New Yorkbased public relations agen cies, including Manning, Selvage & Lee and Chandler Chicco Agency. Ms. Kessler also was assistant director of press relations at Mount Sinai Hospital. In Ms. Kessler’s new role, she oversees media campaigns for a wide range of the agen cy’s healthcare clients including Alkermes, Aventis Behring, Clearant, Eli Lilly & Co., Pfizer, and Pharmacia. Dr. Pankaj KUMAR Paul SAATSOGLOU IMS Strengthens U.S. Consulting Team with Two Recognized Industry Leaders IMS Health, Fairfield, Conn., has added two key members to its U.S. consulting team. Paul Saatsoglou joins as practice area leader for global resource optimization, and Pankaj Kumar, Ph.D., as practice area leader for advanced research and segmentation. The appointments reinforce IMS’s commitment to expand and strengthen its consulting business to support pharmaceutical client needs in areas such as marketing effectiveness, sales opti mization, and portfolio management. As practice area leader for global resource optimization, Mr. Saatsoglou is charged with spearheading initiatives to help clients allocate marketing resources globally and across port folios, using stateoftheart modeling and analytical techniques. He also is responsible for incorporating primary research elements to deliver clients complete consulting offerings that incorporate both marketplace intelligence and customer insights. Mr. Saatsoglou brings to IMS more than 20 years of pharmaceutical industry experience, most recently serving as senior VP of the healthcare division of Data Development Corp. and VP of market research and business intelligence at BristolMyers Squibb. A Ful bright scholar, Mr. Saatsoglou received his B.A. in physics from Franklin and Marshall and his M.S. from the Wharton School, Uni versity of Pennsylvania. He also has complet ed doctoral work in statistics and operations research at the Wharton School. As practice area leader for advanced research and segmentation, Dr. Kumar provides his expertise to help clients apply a variety of advanced research techniques, such as physician and patientlevel response modeling, to better understand what drives prescribing choices and behaviors. He also helps clients design, develop, and implement effective marketing strategies through integrated market segmentation, tar geting, and brand positioning. Dr. Kumar comes to IMS from academia 94 F e b ru a r y 200 3 PharmaVOICE TALENT pool where, most recently, he was an assistant pro fessor of marketing at the Johnson Graduate School of Management, Cornell University. Dr. Kumar received his Ph.D. in marketing with a minor in economics from the State Uni versity of New York at Buffalo and also received a bachelor’s degree in mechanical engineering from M.S. University in India. Bindu SHAH PharmaStrat Inc. Appoints Manager of Strategic Services Bindu Shah has joined PharmaStrat Inc. as man ager of strategic services. In this role, she is respon sible for the design and implementation of strate gic projects for Pharma Strat clients across several therapeutic areas. Among Ms. Shah’s key responsibilities are opportunity analysis, survey design, educational programs, and client report preparation. PharmaStrat, Flemington, N.J., provides insight and impact to the nation’s leading pharmaceutical compa nies. Before joining PharmaStrat, Ms. Shah was with a Bostonbased strategic consulting firm serving the pharmaceutical industry. In that role, she executed market assessments and con ducted research and analysis of etiology and pathogenesis of diseases, including myocardial infarction, stroke, angina, peripheral vascular diseases, epithelial cancers, and psoriasis. Ms. Shah earned a master’s degree in med ical sciences from Boston University and a B.A. in biology from Brandeis University. David STEIN ClinPhone Adds Strategic Business Development Director ClinPhone Inc., a provider of Internet and telephonebased clinicaltrial management solutions for the pharmaceutical and biotech nology industries, has appointed David Stein as director of strategic business development. ClinPhone’s U.S. headquarters are in Princeton, N.J., and its global base is in Nottingham, U.K. Mr. Stein joins the company from Phase Forward, where he held the position of strate gic director of EDC solutions, after it acquired Provenda, which he cofounded. In his new role at ClinPhone, Mr. Stein works with ClinPhone’s senior management team on the development and achievement of the company’s strategic business goals as well as promoting a process for new product devel opment, implementation, and evaluation. He is specifically responsible for working in partnership with ClinPhone’s global mar keting director to manage the development of ClinPhone’s U.S. market and further increase market reach and revenue. He also is charged with developing and implementing a tactical plan for the U.S. business development and marketing teams and support the company’s partnership program. James WATSON LifeSciences Merchant Bank Appoints Director,Strategic Partnering Services Group James Watson has joined Burrill & Co., a San Franciscobased lifesciences merchant bank, as director in its strategic partnering ser vices group. Mr. Watson’s primary focus is on assisting companies to initiate, structure, and close business and corporate development trans actions. He leads a variety of alliances, includ ing strategic collaborations, product and tech nology licensing, and mergers and acquisitions. Mr. Watson has considerable experience in both commercial development and strategic collaborations. Before joining Burrill & Co., Mr. Watson held senior VP positions with Incyte Genomics with responsibility for busi ness development and marketing. Before Incyte, Mr. Watson served as senior VP of business development and then general man ager of Chemdex. A Fulbright Scholar, Mr. Watson received his MBA from Indiana University and a B.A. in economics from Portsmouth University, U.K. Supplier POOL Daniel J. MALCOLM IT Consulting Firm Daou Names CEO As part of its continuing evolution and repo sitioning in the marketplace, Daou Systems Inc., a provider of IT consulting and management ser vices to healthcare organizations, has named Daniel J. Malcolm CEO and company director. Former CEO and Chairman of the Board James T. Roberto has assumed a new role as working chairman, continuing with his responsibilities at the board level while assuming a number of defined strategic planning, business develop ment, and financial advisory responsibilities for the company, principally under Mr. Malcolm’s direction. A seasoned IT leader with strong executive management experience at IBM and Siemens, Mr. Malcolm joined Daou, Exton, Pa., in August 2001 after serving as vice chairman and chief operating officer of LaserLink.net, where he helped expand and energize the com pany for a subsequent sale to Covad Commu nications Inc. Dr. Jo WEBBER Regulatory Compliance Solutions Company InnaPhase Selects CEO Jo Webber, Ph.D., has joined InnaPhase Corp. as CEO. Dr. Webber previously held the position of executive VP of sales and opera tions for the organization. InnaPhase, Philadelphia, is a leading supplier of regulato ry compliant technology solutions for the pharmaceutical and biotechnology industries. In her new role, Dr. Webber oversees all of the company operations and continues to lead the companywide effort to develop and mar ket innovative technology solutions for the lifesciences industry. Dr. Webber also joins the InnaPhase board of directors. Media POOL Brian FESCOE Intellisphere LLC Appoints Web Developer Intellisphere LLC, Plainsboro, N.J., has named Brian Fescoe as the Web developer for all of the company’s future online initiatives. Intellisphere LLC’s flagship publication is MD net guide: Primary Care, which integrates both electronic and print media to provide physi cians with userfriendly access to online medical content. In addition, Intellisphere also publish es eight additional health resources that inte grate print and online media to review, describe, and compile resources for the particu lar specialty addressed by the publication. Mr. Fescoe joins Intellisphere after working as the senior Web designer for Promedia Inc. Mr. Fescoe brings a wealth of experience to Intellisphere, including work in concept design, Website development, computer graphics, and multimedia applications. Noam SHOSHAN MultiMedia Healthcare/Freedom appoints director of strategic communications MultiMedia Healthcare/Freedom has appointed Noam Shoshan to the newly creat ed position of director of strategic communi cations. The new position is expected to 95 PharmaVOICE F e b ru a r y 2 00 3 TALENT pool strengthen collaborative programs. The Plainsboro, N.J. based company publishes medical magazines and provides educational pro grams. In his new role, Mr. Shoshan will work directly with pharmaceu tical marketers, helping them create collabora tive programs with professional associations across a broad spectrum of disease categories. Specific responsibilities include the develop ment and implementation of credentialed pro grams, using MMHC/Freedom’s peerreviewed journals and conference capabilities to establish clinical guidelines for healthcare professionals. He also is part of the company’s medical edu cation division, Programs in Medicine. With more than a decade of experience, Mr. Shoshan joins MMHC/Freedom after a brief tenure with ArcLight Systems. Before ArcLight, he spent seven years at Medical Eco nomics/Thomson Healthcare, where he was national sales manager. Mr. Shoshan created and sold many cobranded medical education and practice management programs. He is a graduate of Fairleigh Dickinson University in Madison. Agency POOL Jennifer ALAMPI Scott ANNUZIATA Matthew ARNOLD Myka CRAIG Orlando FRANCO Marcia GODDARD John HIGGINS Debra KLECZ Larry LANNINO Tamara PHOTIADIS Jennifer SCHROTT Torre Lazur McCann Healthcare Announces Key NewHires and Promotions Torre Lazur McCann Healthcare has announced several key additions and promo tions within the client services and creative departments. Headquartered in Parsippany, N.J., Torre Lazur McCann Healthcare World wide is the third largest healthcare communi cations network Scott Annuziata has been hired as senior graphic designer; Matthew Arnold has been hired as graphic design supervisor; Myka Craig has been hired as graphic design super visor; John Higgins has been hired as VP and account group supervisor; Larry Lannino has been hired as VP and management supervisor; and Jennifer Schrott has been hired as account supervisor. The company also has promoted Jennifer Alampi to VP and group creative director, art; Orlando Franco to Comp Studio Manager; Marcia Goddard to associate creative director, copy; Debra Klecz to senior art director; and Tamara Photiadis to studio director. Kristen BEAKLEY George BROWN Lisa BURCH Lisa CONNELL Lori DIDIEO Tara GLEESONMULVANEY Jeffrey HACK Mark Forbes IRVING Amy KORTMAN Kirk LAWSON MaryAnn MCADAMS Sarah MCGRATH Joseph MARANZANI Veronica MELISSAS Michael MELUCCI Frances SMALL Laura YAROSH CommonHealth Agencies Announce Promotions and Hires Two CommonHealth agencies have announced recent promotions and hires. Health Learning Systems, Wayne, N.J., Com monHealth’s founding medicaleducation unit, has announced six promotions and two new hires. Mark Forbes Irving has been promoted to senior VP of professional relations from his previ ous position as VP of pro fessional relations. Mr. Irving has been employed with HLS since July 2001. George Brown has advanced to associate medical director. Previously, he held the title of medical writer. Michael Melucci has moved to account manager from associate program director. Lori Didieo has been pro moted to senior creative designer from her previous position as graphic design er. Veronica Melissas has been promoted to supervi sor and meetings coordi nation. Previously, she held the title of meetings coordinator. Lisa Burch has advanced to senior mana er for meetings, from meetings manager. The company also has hired Joseph Maranzani, who comes to Health Learning Systems as an associate program director. Before his employment with HLS, Mr. Maranzani was an associate program manager at GeoMed Glob al Communications, a divi sion of Thomson Health care. MaryAnn McAdams joins HLS as a senior edi tor. Previously, Ms. McAdams served as presi dent of McAdams Com munications Services. Thomas Ferguson Associates, Parsippany, N.J., CommonHealth’s founding professional advertising and promo tion unit, has announced six promotions and three new hires. Frances Small has been promoted to group art director from her previous position as senior art direc tor. Tara GleesonMul vaney has advanced to account supervisor. Previ ously, she held the title of senior account executive. Kristen Beakley has been promoted to senior traffic coordinator from her previous position as traffic coordinator. Laura Yarosh has moved to senior traffic coordinator from traffic coordina 96 F e b ru a r y 20 03 PharmaVOICE TALENT pool tor. Lisa Connell has been promoted to assistant account executive. Previ ously, she held the title of traffic coordinator. Amy Kortman has advanced to traffic coordinator from traffic assistant. The company also has hired Kirk Lawson as an account group supervi sor. Previously, Mr. Law son served as executive director of Liberty Medi cal LLP, a multispecialty private group practice that specializes in viral illnesses. Jeffrey Hack joins Thomas Ferguson Associ ates as an associate copy writer. Previously, Mr. Hack was a senior admin istrative associate at Ortho Biotech Products LP as part of the company’s Competitive Response Team. Sarah McGrath has been hired as a traf fic coordinator. Immediately before her employment, Ms. McGrath graduated from Elon University in North Carolina. David BULGER Martin MAJCHROWICZ Appointments Announced for DVCWorldwide Companies DVC Worldwide, Morristown, N.J., a marketing and communications agency that creates breakthrough programs using sales promotion, advergaming, experiential mar keting, and interactive solutions techniques, has announced recent hires within its network. Martin Majchrowicz brings more than 10 years of HIV expertise to his role as executive VP at DVCHealthCare Communications. Mr. Majchrowicz will direct the Manhattanbased division of DVC HealthCare Communica tions, focusing on consulting, data dissemina tion, education, and communication to inves tigators and healthcare providers managing patients with HIV. Mr. Majchrowicz’s expertise ranges across healthrelated disciplines, including research, patient education and advocacy, and profession al communications. As project manager of the Cellular Immunology and Cytometry Laborato ry at UCLA, he contributed to the design and implementation of several key studies and pub lications in the area of HIV immunopathogen esis. At AIDS Project Los Angeles (APLA), Mr. Majchrowicz established one of the first HIV specific patient education programs in the country. During his four years at APLA, he also led numerous local and national patient advoca cy efforts focused on healthcare access, HIV related research, and new drug approval. Mr. Majchrowicz graduated from the Uni versity of Southern California and received his master of public health in epidemiology from the University of California, Los Angeles. In addition, DVC ActiveCare has hired a behavioral marketing expert to advance brand acceleration capabilities. David Bulger has been hired as executive VP and behavioral strategist to build and evolve proprietary con sulting and analytical offerings that accelerate target audience transactions through a com municationsbased synthesis of behavioral sci ence and marketing communications. Mr. Bulger brings years of leadership in interactive and behavioral marketing, partic ularly in the healthcare arena. In 1994, he cofounded MicroMass Com munications Inc., one of the first agencies focused on combining behavioral methodolo gies with applied mass media to engage indi vidual target consumers and move them along the purchase cycle. MicroMass evolved from Mr. Bulger’s work as director of software and media development at the University of North Carolina’s Health Communications Research Laboratory, where he coauthored a methodology for mapping and forecasting behavior change from target specific messaging. Scott BANDA Sharon BRADY Charlotte CUSTIS John HIRVELA Brian HUBER Kym LEE Steve LEHR Russ PARKEL M.J. PICARD Valarie WITTEMIRE Gerbig,Snell/Weisheimer,Y Announce Hires and Promotions Gerbig, Snell/Weisheimer, one of the largest independent advertising agencies in the world, has promoted Charlotte Custis to VP and account director of direct marketing. In this new role, she will oversee direct mar keting and customer relationship marketing programs. GSW is a sub sidiary of inChord Com munications Inc., a global group of communications companies providing cus tomized marketing solu tions with a single point of accountability. Since joining Colum bus, Ohiobased GSW in 1999, Ms. Custis has held positions with increasing responsibil ities and has led the development of a special ty marketing group within the agency that focuses on relationship marketing programs. Before GSW, Ms. Custis was management supervisor for Rapp Collins Omnicom, where she managed branding, direct marketing, advertising campaign, and growth of assigned client accounts. She also oversaw the overall direction, creative, and new business develop ment of her team. Ms. Custis holds a bache lor’s degree in art history from The Ohio State University and has been honored with direct marketing and advertising awards. Scott Banda has been named senior art director. Mr. Banda is responsible for concept, design, pre sentation, execution, and production for one of GSW’s pharmaceutical accounts. In addition, he provides guidance to other artists within the team. Before GSW, he was senior art director at J. Walter Thompson. Mr. Banda holds a bachelor’s degree in adver tising design from Glassboro St. College. He also attended The Creative Circus for addi tional training. Sharon Brady has been named group art supervi sor. In this position, she leads the creative concept ing and art direction for one of the agency’s phar maceutical accounts. Before GSW, Ms. Brady was associate creative director at Fahlgren, where she was responsible for concept and art direction for print and broadcast. Ms. Brady holds a bachelor’s degree in advertising design from Florida State Uni versity. Bryan Huber has been named group art supervi sor. In this role, Mr. Huber is responsible for the overall concept, art direction, and creative supervision for one of GSW’s pharmaceutical accounts. Before GSW, he was assistant creative director for Be Creative, where he oversaw the creative teams for his various accounts. Mr. Huber holds a bachelor’s 97 PharmaVOICE F e b ru a r y 2 00 3 TALENT pool degree in graphic design and photography from Miami University. Steve Lehr has been named account supervi sor. Mr. Lehr serves as liaison between the client and creative team for one of GSW’s consumer accounts. Before GSW, he was account supervi sor at Doe Anderson. Mr. Lehr holds a bachelor’s degree in journalism with an advertising emphasis from the University of Wisconsin. M.J. Picard has been named associate art director. In this role, Ms. Picard manages the daytoday creative work for two of GSW’s consumer accounts. Before GSW, she was a designer at IDS, Columbus Division, where she created artwork and design and produced blueprint documentation for a screen print ing/manufacturing company. Ms. Picard holds a bachelor’s degree in visual communications design from The Ohio State University. Valarie Wittemire has been named produc tion director. Ms. Wittemire is responsible for managing the production on several pharma ceutical accounts, including creating estimates, managing outside vendors, developing chronologies, and helping to ensure the quality of a project. Before GSW, she was a sales repre sentative at Kenwel Printers Inc., where she was responsible for new sales growth and develop ment. Ms. Wittemire holds a bachelor’s degree in graphic design from Kent State University. In addition, John Hirvela and Kym Lee have been hired to fill the positions of VP and account director. Both will provide leadership and strategic guidance for GSW’s pharmaceutical accounts. Mr. Hirvela joins GSW from RTC Rela tionship Marketing in Washington, D.C., where he was VP, account direc tor. Before RTC, he was an account supervisor at Wunderman and Ross Toy Communications. Mr. Hirvela holds a bachelor’s degree in English and business management from Eastern Michi gan University in Ypsilanti, Mich. Ms. Lee comes to GSW from Enterasys Networks, a division of Cabletron, where she was director of strategic development. Before Enterasys Network, Ms. Lee was new business development manager/director of marketing for Rexam Plc. and was a senior product man ager for Borden Inc. Ms. Lee holds a bachelor’s degree in mar keting and photography from Miami Univer sity in Oxford, Ohio, and a master’s degree in business administration from the University of Dayton in Dayton, Ohio. She also has been a mentor for the Buck Rodgers Leadership Program at Miami University and has served on the board of directors for the Hanna Neil Center for Children in Columbus. Y, a New Yorkbased inChord company offering strategic consulting and branding ser vices, has appointed Russ Parkel as managing director of its New York office. In this role, Mr. Parkel will manage the daytoday operations of Y, as well as oversee new business activities and work with Y’s senior managers to lead client brand development efforts. Before Y, Mr. Parkel spent more than six years working at WPP Group, most recently at J. Walter Thompson in New York, where he served as senior partner, global manage ment director, overseeing the Merrill Lynch account. He also held senior management positions at Hill & Knowlton in New York, JWT in Japan, and JWT in Sydney. Mr. Parkel holds a bachelor’s degree in busi ness administration from the University of South ern California and is cur rently a member of Thun derbird International Management School’s global advisory board. Marisa CIMBAL Susan GOLDBERG Christina HOSMER Peter HURWITZ David P. LANE George LIAO Philip MAHIN Linda MARENUS Andrea PERLMANWOLFF Melody PETRUCCELLIUYSAL George ROGAN Adrienne ZION Healthworld Bolsters Staff for Medical Education Divisions Healthworld Corp. has added senior staff to Colwood Healthworld, a medical education division of Healthworld. Healthworld, New York, is an international communications organization specializing in healthcare. Joining Colwood as a senior scientific asso ciate is George Rogan. Previously, Mr. Rogan was a scientific supervisor at Phase V Com munications. In addition, Linda Marenus comes to Colwood as publications manager from CRC Press Inc., where she was a science copywriter. Adrienne Zion, Ed.D. also joins as medical writer from Body Focus NYC, where she was director of health education and fit ness training. In account management services, Philip Mahin comes on board as VP and account group supervisor. Before joining Colwood, Mr. Mahin was senior VP and management super visor at IntraMed Educational Group. The company also has announced promo tions and additions of editorial/managerial staff to Falk Healthworld, a medical education division of Healthworld. In account services, Andrea PerlmanWolff and Melody PetruccelliUysal were both pro moted from VP, group supervisor, to senior VP, group supervisor. In addition, Peter Hur witz was promoted from VP, account supervi sor, to senior VP; Susan Goldberg was pro moted from account executive to account supervisor; and George Liao was promoted from program manager to program director. David P. Lane has joined the company as senior editor. Before joining Falk Health world, Mr. Lane was medical editor of the IntraMed Educational Group at Sudler & Hennessey. In addition, Christina Hosmer joins Falk Healthworld as program manager. Previously, she was junior account executive at Grey Healthcare Group. Also joining Falk Healthworld is Marisa Cimbal as account supervisor. She most recently was an account supervisor at Torre Lazur Communications. Lloyd EASTERS DeLor Hires Business Development Director to Support Growing Pharmaceutical Business Lloyd Easters has joined DeLor as director of business development. DeLor is a brand identity consultancy focused on the pharmaceutical indus try and based in Louisville, Ky. Before joining DeLor, Mr. Easters spent 10 years working in both sales and marketing management positions in the pharmaceutical industry. Most recently, he worked for Organon Pharmaceuticals as dis trict manager for the Women’s Healthcare division in the Midwest Region. Please send your personnel announcements to [email protected]. 98 F e b ru a r y 200 3 PharmaVOICE

Download PDF